Abstract: The invention features psilocin formulations for intravenous infusions including psilocin benzoate salt in combination with an antioxidant.

Abstract: A medicament and method for treating circulatory diseases accompanied by inflammation of a cardiovascular system related to IL-6 and/or IL-1? and a medicament and method for treating circulatory diseases accompanied by inflammation of a cardiovascular system related to IL-6 and/or IL-1?. The method involves administering a medicament including an IL-6 and/or IL-1? suppressor including a compound represented by the following formula (I) where R1 and R2 are each independently a hydrogen atom or a methyl group, or a pharmaceutically acceptable salt thereof.

Abstract: RhoA inhibitors that can covalently bind RhoA are described herein. The disclosed RhoA inhibitors show improved inhibitory efficacy (i.e., an IC50 value down to about 400 nM). Further, the disclosed RhoA inhibitors can specifically bind RhoA over other GTPases, such as other Ras GTPases (e.g., K-Ras and N-Ras) and particularly other Rho GTPases (e.g., Cdc42 and Rac1). The combination of high RhoA inhibitory efficacy and high RhoA specificity of the disclosed RhoA inhibitors allow these compounds to show high cytotoxicity and anti-metastatic effects in cancer cells, with negligible toxicity in normal cells, in vitro and in vivo. Pharmaceutical compositions containing the RhoA inhibitors and methods of using the RhoA inhibitors or pharmaceutical composition thereof for treating cancer are also described.

Abstract: Glutathione deficiencies and deficiencies in glutathione synthetase activity, and the methods for the treatment thereof.

Abstract: The present invention relates to a method for suppressing deleterious effects of senescence in a mammal. The method includes administration to the mammal of a composition comprising therapeutically effective amount of ergothioneine, or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof. In some embodiments, the composition suppressing deleterious effects of senescence is by down-regulation of p21 and/or SA?G.

Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.

Abstract: Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).

Abstract: Treatment of non 24 sleep wake disorder using gaboxadol or a pharmaceutically acceptable salt thereof is provided. Pharmaceutical compositions that may be used to improve one or more symptoms of non 24 sleep wake disorder are provided.

Abstract: An subject of the present invention is (S)-2-Methyl-5-(1-methyl-2-pyrrolidinyl)pyridine for use in in a method for the treatment of nicotine dependence in an amount of 0.1-5% by weight, a pharmaceutical composition comprising (S)-2-Methyl-5-(1-methyl-2-pyrrolidinyl)pyridine for use in a method for the treatment of nicotine addiction in an amount of 0.1-5% by weight per composition of oral, inhalation and dermal products for humans. It is also an subject of the present invention to use a composition comprising (S)-2-Methyl-5-(1-methyl-2-pyrrolidinyl)pyridine in an amount of 0.1-5% by weight as a substitute for a nicotine composition in food products, inhalation and dermal products for humans, the composition being in liquid or solid form and selected from such as e-cigarettes, e-cigarette liquids, chewing tobaccos, oral pouches, chewing gums, candies, lollipops, strips, dragees, jelly beans, lozenges, tablets, snuffs, shisha-type smoking mixtures, toothpastes, inhalation mixtures, inhalers or skin patches.

Abstract: Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists or a pharmacologically acceptable salt thereof are disclosed. The compositions contain the therapeutic active compound with non-ionic polymer and ionic polymer, binder and fillers in either matrix pellet, matrix tablet or coated pellets. The compositions provide a pH-independent in vitro release profile with NMT 70% in one hour, NMT 85% in 4 hour, and NLT 80% m 8 hours. The compositions are useful for the treatment of CNS disorders, such as Treatment-Resistant Depression (TRD) and Fragile X Syndrome.

Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperdinyl-formamide (or similar) structure which function as adrenoreceptor antagonists, and their use as therapeutics for the treatment and/or prevention of pain and related conditions. In addition, the present invention provides compositions comprising a mixture of opioid receptor agonist compounds and such adrenoreceptor antagonists for the treatment and/or prevention of pain and related conditions.

Abstract: The present invention relates to NLRP3 protein degradation inducing compounds. Specifically, the present invention provides a bifunctional compound in which an NLRP3 protein binding moiety and an E3 ubiquitin ligase binding moiety are connected by a chemical linker, a method for preparing the same, a method for degrading NLRP3 protein using the same, and the use for preventing or treating NLRP3 inflammasome-related diseases.

Abstract: The invention relates to a plurality of coated particles containing a solid core containing one of the compounds lenalidomide and pomalidomide, or a pharmaceutically acceptable salt thereof. The core has a mean diameter of the between 0.1 pm and 50 pm. The core is a coated by a coating surrounding, enclosing and/or encapsulating the core. The coating contains a mixed oxide selected from the group consisting of iron oxide, zinc oxide, silicon oxide, titanium oxide, and aluminium oxide.

Abstract: Oral pharmaceutical solution comprising lenalidomide or a pharmaceutically acceptable salt thereof as active ingredient and a pharmaceutically acceptable carrier comprising a glycol, a polyol and water, wherein the pH of the solution is from 1.0 to 3.0.

Abstract: Disclosed are methods and products for improving the quality of sperm, methods for treating subjects to improve sperm quality or improve fertility, and use of sperm with improved quality in assisted reproductive technologies, including exposing the sperm to BGP-15 and/or a derivative thereof, such as BGP-15, propanolol, bimoclomol, arimoclomal, NG94, iroxanadine, and/or a pharmaceutically acceptable derivative, prodrug, solvate, salt, tautomer, stereoisomer, and/or racemate thereof.

Abstract: Methods and compositions for treating or preventing non-viral tick-borne diseases and symptoms thereof by administering a long half-life 8-aminoquinoline, such as tafenoquine, are disclosed. Kits including a means for testing for a non-viral tick-borne disease and/or symptoms thereof and a long half-life 8-aminoquinoline, such as tafenoquine, are disclosed.

Abstract: A nanoparticle for delivering an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor to a subject and methods for treating inflamed tissue in a subject using the nanoparticle.

Abstract: This invention provides a method that combines a checkpoint inhibitor and a glucocorticoid receptor modulator to treat cancer, e.g., a checkpoint inhibitor sensitive cancer.

Abstract: The present invention relates to the use of bifunctional compositions in methods of treating or preventing cancer. The compositions comprise a DNA ligand and a protein ligand for the treatment or prevention of cancer, wherein the DNA ligand interferes with DNA metabolism and the protein ligand interferes with signalling pathways. The invention also relates to compositions, compounds and medicaments comprising a DNA ligand and a protein ligand.

Abstract: Provided are a new pharmaceutical composition and a method for treating and/or preventing autism spectrum disorder, fragile X syndrome, and/or an autism spectrum disorder-like symptom. A pharmaceutical composition for the treatment and/or prevention of autism spectrum disorder, fragile X syndrome, and/or an autism spectrum disorder-like symptom, comprising buprenorphine or a pharmaceutically acceptable salt thereof and/or morphine or a pharmaceutically acceptable salt thereof.

Abstract: Methods are provided for preventing, reducing, and/or treating contrast-induced acute kidney injury which include administering an inhibitor of fatty acid oxidation to a patient in need thereof. Also provided are methods involving use of trimetazidine or pharmaceutically acceptable salts thereof for the prevention and/or treatment of contrast-induced acute kidney injury. Methods are also provided for preventing and/or treating contrast-induced acute kidney injury which include administration of one or more of trimetazidine, etomoxir, oxfenicine, perhexiline, mildronate, or ranolazine, or pharmaceutically acceptable salts of any of the preceding.

Abstract: The present disclosure provides novel cell compositions engineered to express at least a chimeric antigen receptor and a survival factor. Methods of using such cell compositions are also described.

Abstract: An object of the present invention is to provide a pharmaceutical composition for preventing and/or treating heart failure. The invention relates to a pharmaceutical composition for preventing and/or treating heart failure, comprising a compound represented by formula (1), a salt thereof, or a prodrug thereof: wherein A is an optionally substituted benzene ring; B is an optionally substituted aryl or an optionally substituted heteroaryl; X is an oxygen atom or a sulfur atom; Y is a nitrogen atom or a carbon atom; of Y is a single or double bond when Y is a carbon atom, or of Y is a single bond when Y is a nitrogen atom; each R1 independently represents lower alkyl, or two R1s may be bound to each other to form a spiro ring or a crosslinked structure, or two R1s may be bound to each other to form a saturated fused heterocycle together with nitrogen and carbon atoms constituting a ring containing Y; p is 0, 1, or 2; or (R1)p is oxo.

Abstract: Disclosed herein are compositions comprising Plinabulin and one or more immune checkpoint inhibitor for treating cancer. Some embodiments relate to methods of treating cancer by co-administering Plinabulin and one or more immune checkpoint inhibitor to a subject in need thereof.

Abstract: Disclosed herein are methods of treating, preventing or ameliorating a disease or condition associated with cancer or a tumor. In some embodiments, the method includes administering a compound of Formula (I) to a subject in need thereof wherein the cancer or the tumor is or becomes resistant to one or more immune checkpoint inhibitors.

Abstract: The instant invention relates to combinations of LSD1 inhibitors (or pharmaceutically acceptable salts thereof) and gilteritinib (or a pharmaceutically acceptable salt thereof). The combinations are particularly useful for treating myeloid cancers, such as acute myeloid leukemia or myelodysplastic syndrome.

Abstract: The invention encompasses the novel class of compounds represented by the Formula (I), (II), (III) and (IV) below, which are modulators of ROR?t The invention also encompasses pharmaceutical compositions which include the compounds shown above and methods of treating or preventing autoimmune diseases and antibody mediated rejection.

Abstract: Described herein are methods and compositions that include use of one or more poly (ADP-ribose) polymerase 1 (PARP1) inhibitors and one or more inhibitors of activated stromal/activated cancer-associated fibroblasts. Such methods and compositions are useful for treating cancer. Further disclosed are PARP1 inhibitors, and inhibitors of activated stromal/activated cancer-associated fibroblasts used for the methods.

Abstract: A method for inhibiting the release of tumor necrosis factor (TNF) from mast cells including administering an effective amount of an inhibitor to a subject; wherein the inhibitor is an inhibitor that selectively targets conventional mitogen activated protein kinase signaling pathways; and allowing the inhibitor to interact with mast cells or their signaling pathways involved in TNF release, thereby inhibiting TNF release. Also disclosed is a method for preventing the conversion of membrane-bound tumor necrosis factor (mTNF) to soluble tumor necrosis factor (sTNF) in mast cells using an inhibitor including administering an effective amount of the inhibitor to a subject; wherein the inhibitor is a chemical compound that selectively targets conventional mitogen activated protein kinase signaling pathways; and allowing the inhibitor to interact with mast cells or the enzymatic machinery responsible for the cleavage of mTNF within mast cells, thereby inhibiting the conversion of mTNF to sTNF.

Abstract: The present disclosure relates to a class of pyrimidine derivatives having immunomodulating properties that act via TLR7 which are useful in the treatment of viral infections and cancers.

Abstract: Described herein are methods for treating preterm labor, stopping labor prior to Cesarean delivery, preventing preterm labor, or controlling the timing of parturition by administering a chemical compound, such as a muscarinic receptor antagonist, preferably a M3 receptor antagonist, or a ?-3 adrenergic agonist. Also described are methods for treating preterm labor, stopping labor preparatory to Cesarean delivery, preventing preterm labor, or controlling the timing of parturition by administering an effective amount of transdermal stimulation, posterior tibial nerve stimulation or another form of non-invasive or invasive neuromodulation, unstimulated or stimulated acupuncture, magnetic field therapy, or vibratory stimulation. These methods may be practiced individually, in combination with each other, or in combination with known tocolytic methods or medications.

Abstract: Provided herein are methods of treating systemic lupus erythematosus including lupus nephritis, in particularly active proliferative lupus nephritis in a subject with (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo-[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to a combination comprising (i) a recombinant protein comprising interleukin-12 (IL-12) and an antibody binding the extra-domain B (ED-B) of fibronectin, or a target binding fragment or derivative thereof, and (ii) a kinase inhibitor, and its use for treatment of cancer.

Abstract: The present disclosure relates to a compound for use in treating chronic obstructive pulmonary disease (COPD) in a patient, which compound is ensifentrine or a pharmaceutically acceptable salt thereof, wherein the patient has a blood eosinophil count of <300 cells/?L, <150 cells/?L, or <100 cells/?L.

Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with CDK4/6 inhibitors.

Abstract: Provided herein are inhibitors of SLC26A3, which is an anion (Cl?, HCO3?, oxalate) exchanger expressed in intestinal epithelial cells. SLC26A3 inhibitors have potential utility for treatment of constipation including chronic idiopathic constipation (CIC), opioid-induced constipation (OIC), constipation-predominant irritable bowel syndrome (IBS-C), cystic fibrosis-associated constipation, meconium ileus, distal intestinal obstruction syndrome, calcium oxalate kidney stone disease, enteric hyperoxaluria and primary hyperoxalurias.

Abstract: The present disclosure relates to antibiotic compositions and administration methods for treatment of chronic low back pain.

Abstract: The present invention provides crystalline forms of a pentaaza macrocyclic ring complex according to the following formula: Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of disease states.

Abstract: A composition for treating hypogonadism comprises testosterone androstane steroid derivative (TASD), an aromatase inhibitor, and a delivery portion (DP). The TASD, aromatase inhibitor, and DP are combined to form a solution adapted to be administered transdermally. The method comprises the steps of administering a therapeutically effective amount of TASD sufficient to maintain a total serum testosterone level within a therapeutic/stabilized range; administering a therapeutically effective amount of an aromatase inhibitor, sufficient to maintain an estradiol level at or below 35 pg/mL, the TASD and aromatase inhibitor administered simultaneously, via spray. Aspirin is administered if the patient is determined to have an elevated hemoglobin level. In certain embodiments, the hemoglobin level is determined to be elevated if the hemoglobin level is greater than or equal to 17 g/dL and, if elevated, blood is removed from the patient, in therapeutic amounts.

Abstract: A method of treating hypogonadism in a human male patient comprises the steps of administering a therapeutically effective amount of a testosterone androstane steroid derivative (TASD) such as testosterone cypionate sufficient to maintain a total serum testosterone level within a therapeutic/stabilized range. A therapeutically effective amount of an aromatase inhibitor, such as anastrozole, sufficient to maintain an estradiol level at or below 35 pg/mL and an estrogen level above a predetermined level may be administered. A therapeutically effective amount of aspirin is administered if the patient is determined to have an elevated hemoglobin level. In certain embodiments, the hemoglobin level is determined to be elevated if the hemoglobin level is greater than about 16 g/dL and blood is removed from the patient, in therapeutic amounts, if the hemoglobin level is greater than 17 g/dL. In certain embodiments, the serum total testosterone level therapeutic/stabilized range is between about 605-1051 ng/dL.

Abstract: A method of treating a cholestasis liver condition in a subject in need of such therapy, comprising administering to the subject a muricholic acid (MCA), such as ?-MCA, ?-MCA, ?-MCA, or a glycine- or taurine-conjugated MCA, such as a glycine-conjugated ?-MCA, a glycine-conjugated ?-MCA, a glycine-conjugated ?-MCA, a taurine-conjugated ?-MCA, a taurine-conjugated ?-MCA, a taurine-conjugated ?-MCA, or a pharmaceutically-acceptable salt of any of the above.

Abstract: Bioresorbable cationic steroidal antimicrobial (CSA) compounds having a structure of Formula I, II or III, or salt thereof, wherein at least one of R1-R18, (e.g., R18) includes a mono-or diglyceride of a fatty acid attached via an ester linkage and at least one R1-R18, (e.g., R3, R7 and R12) is an amino acid linked to the steroidal backbone via an ester or amide linkage: wherein: R18 has the following structure: —R19—(C?O)—O—C—CR20—CR21 where R19 is omitted or selected from alkyl, alkenyl, alkynyl, and aryl, and R20 and R21 are independently selected from hydroxy, alkylcarboxy, and aminoalkylcarboxy, provided that at least one of R20 or R21 is an alkylcarboxy, R3, R7 and R12 have the following structure: R24R23N—R22—(C?O)—X— where R22 is substituted or unsubstituted alkyl, X is oxygen or nitrogen, and R23 and R24 are independently hydrogen, alkyl, alkenyl, alkynyl, or aryl.

Abstract: Disclosed in the present invention are a steroid compound, and a preparation method therefor and the use thereof. The structure of the steroid compound is as shown in formula I, and the definition of each substituent in the formula are as described in the description and claims. The steroid compound of the present invention is a steroid compound having the dual functions of excellent AR antagonistic activity and AR degradative activity, has the characteristics of good druggability and safety, and can be used for treating diseases related to an AR signaling pathway.

Abstract: The invention provides an improved method for preparing lysine acetylsalicylate?glycine (LASAG) that allows for high yields without the need for an addition of seed crystal, as well as yielding controlled, small particle sizes (median particles size preferably <40 ?m) and high stability of the LASAG. Advantageously, the method can be performed at room temperature without negatively impacting yield or particle properties. The invention also provides the LASAG obtained from said method, and its uses as a medicine.

Abstract: The present disclosure relates to compositions, including foamable compositions with improved properties, such as those comprising waxes, emollients, foam adjuvants and/or active agents, and methods for preparing and using them.

Abstract: A fixed dose combination formulation drug comprised of three cannabinoids, namely cannabidiol, cannabichromene, and cannabigerol, and of three terpenes, namely alpha-terpinene, bisabolol, and camphene, in an orally available pharmaceutical carrier, for the alleviation of the adverse effects of cancer chemotherapy agents, including adverse effects on the gastrointestinal tract, the chemoreceptor trigger zone, and the peripheral nervous system, and that shows activity adjunctively against ovarian cancer, particularly ovarian cancer that is therapeutically platinum-resistant or platinum-sensitive.

Abstract: Methods of feeding animals are disclosed whereby feed additives are provided that modulate the gut microbiome to prevent or treat dysfunctions in a gastrointestinal barrier. The present disclosure further relates to methods of feeding animals by providing feed additives that modulate the gut microbiome to prevent or treat infections.

Abstract: The present invention is directed to methods for inhibition of HIV reverse transcriptase, treatment of infection by HIV, prophylaxis of infection by HIV, and the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC by administering a compound of structural Formula I or a pharmaceutically acceptable salt or co-crystal thereof, wherein X is —F or —Cl, less frequently than once daily.

Abstract: A use of one or more lipid compounds in the delivery of nucleic acids, and a lipid nucleic acid mixture, pharmaceutical composition or kit comprising the lipid compounds and nucleic acids. The lipid compounds provided above can promote the absorption, particularly oral absorption, of nucleic acids, and promote the entry of nucleic acids into target sites in a subject in need thereof.

Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of plasma prekallikrein (PKK). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of PKK protein in a cell or animal.